November 28, 2014
Thirteen active pharmaceutical ingredients (APIs)/23 products including Nippon Kayaku’s and Celltrion’s Infliximab BS for IV Infusion 100 mg “NK” and Infliximab BS for IV Infusion 100 mg “CTH”, which are biosimilars of the rheumatoid arthritis (RA) treatment Remicade (infliximab), received...read more